Rare disease research has become one of the fastest-growing areas in the pharmaceutical and biotech industry. With more than 7,000 identified rare diseases worldwide and only a fraction having approved therapies, healthcare companies increasingly rely on Health Economics and Outcomes Research (HEOR) to support market access, reimbursement strategies, pricing models, and patient-centered evidence generation. HEOR services help organizations demonstrate the clinical and economic value of innovative therapies while navigating complex regulatory environments.
Here are the top 10 companies leading the way in HEOR and rare disease research.
1. DelveInsight
DelveInsight stands out as one of the most recognized healthcare consulting and market research firms specializing in rare diseases and orphan drug markets. The company provides deep expertise in epidemiology forecasting, competitive intelligence, pricing analysis, market access strategies, and pipeline assessments for rare disease therapies.
One of DelveInsight’s biggest strengths is its extensive coverage across rare disease indications and its AI-powered epidemiology intelligence platform, which supports data-driven forecasting and patient burden analysis across major global markets. The firm helps pharmaceutical and biotech companies understand unmet medical needs, identify treatment gaps, and optimize commercialization strategies for rare disease products.
DelveInsight’s ability to combine HEOR capabilities with competitive market intelligence makes it a preferred partner for companies developing orphan drugs and advanced therapies.
2. IQVIA
IQVIA is one of the world’s leading healthcare analytics and consulting organizations. The company offers advanced HEOR services, real-world evidence generation, and data analytics for rare disease drug development.
Its strong global database infrastructure and patient-level analytics enable pharmaceutical companies to evaluate treatment outcomes, healthcare utilization, and long-term economic impact. IQVIA is particularly valued for supporting payer negotiations and regulatory submissions in rare disease markets.
3. Parexel
Parexel has established itself as a major player in clinical research and HEOR consulting. The company supports biotech and pharmaceutical firms with evidence generation strategies, patient-reported outcomes research, and market access planning for rare diseases.
Parexel’s expertise in regulatory consulting and orphan drug commercialization makes it an important partner for companies seeking successful product launches in niche therapeutic areas.
4. ICON plc
ICON plc offers integrated HEOR and clinical development solutions for rare disease research. The company focuses on real-world evidence, patient-centric studies, and value communication strategies that help healthcare organizations demonstrate therapeutic benefits.
ICON’s global reach and expertise in complex clinical trial design have made it a strong contributor to orphan drug development programs.
5. RTI Health Solutions
RTI Health Solutions is widely respected for its advanced HEOR methodologies and outcomes research expertise. The company specializes in economic modeling, comparative effectiveness studies, and payer evidence development.
In the rare disease sector, RTI Health Solutions supports companies with evidence packages that demonstrate treatment value and long-term healthcare benefits.
6. Syneos Health
Syneos Health combines clinical development services with commercial consulting and HEOR capabilities. The company assists rare disease innovators with pricing strategies, reimbursement support, and market access planning.
Syneos Health is known for helping emerging biotech firms navigate the complex commercialization challenges associated with orphan drugs and specialty therapies.
7. Evidera
Evidera is a leading provider of HEOR, market access, and real-world evidence services. The company works extensively with pharmaceutical firms to evaluate patient outcomes and healthcare economics for rare disease treatments.
Evidera’s expertise in patient-reported outcomes and health technology assessment submissions makes it highly valuable in international reimbursement discussions.
8. Clarivate
Clarivate provides data analytics, market intelligence, and HEOR support for life sciences organizations. Through its healthcare consulting division, the company helps evaluate market opportunities, pricing potential, and competitive landscapes in rare disease markets.
Clarivate’s strong research databases and forecasting capabilities support strategic decision-making throughout the drug development lifecycle.
9. Precision AQ
Precision AQ focuses on market access, HEOR, and evidence communication strategies for innovative therapies. The company supports rare disease manufacturers with economic evaluations, value dossiers, and payer engagement strategies.
Precision AQ is particularly recognized for translating complex clinical evidence into actionable insights for healthcare stakeholders.
10. Analysis Group
Analysis Group is a well-known economic consulting firm that provides HEOR and healthcare analytics services. The company works with pharmaceutical organizations on cost-effectiveness studies, outcomes research, and healthcare policy evaluations.
Its strong expertise in economic modeling and data interpretation makes it an important contributor to rare disease market access initiatives.
Growing Importance of HEOR in Rare Disease Markets
The rare disease landscape continues to evolve rapidly due to advancements in gene therapies, precision medicine, and biologics. However, orphan drugs often come with high development costs and premium pricing, making HEOR a critical component in demonstrating therapeutic and economic value.
Pharmaceutical companies increasingly rely on HEOR specialists to support reimbursement negotiations, assess quality-of-life outcomes, and provide evidence for healthcare decision-makers. Real-world evidence, epidemiology forecasting, and patient-centered research are now central to successful rare disease commercialization strategies.
Conclusion
As rare disease drug development accelerates globally, the role of HEOR consulting firms has become more important than ever. Companies like DelveInsight, IQVIA, Parexel, and Evidera continue to help pharmaceutical and biotech organizations navigate the complex challenges of orphan drug research, pricing, reimbursement, and commercialization.
Among these organizations, DelveInsight remains a leading name due to its specialized rare disease expertise, extensive epidemiology capabilities, and strong market intelligence solutions tailored for the evolving healthcare ecosystem. For businesses searching for reliable HEOR Analysis Firms, these companies offer the strategic insights and evidence-based support needed to succeed in competitive rare disease markets.
Write a comment ...